HLA-B*1502等位基因与抗癫痫药物致不同种族严重皮肤不良反应的研究进展

中国药物警戒 ›› 2011, Vol. 8 ›› Issue (4): 237-239.

HLA-B*1502等位基因与抗癫痫药物致不同种族严重皮肤不良反应的研究进展

程新民¹ , 李莉², 田月洁³

1. 济钢集团有限公司总医院，山东济南250101；
2. 山东省医药工业研究所，山东济南 250033；
3. 山东省药品不良反应监测中心，山东济南 250013

收稿日期:2011-01-13 修回日期:2015-08-27 出版日期:2011-04-10 发布日期:2015-08-27
通讯作者: 田月洁,男,副主任药师,药品不良反应监测。E-mail:tianyuejie@gmail.com
作者简介:程新民,男,主管药师,医院药学。

Recent Advance on the Association Between HLA-B*1502 Allele and Severe Cutaneous Adverse Reactions in Different Race Induced by Anti-epileptic Drugs

CHENGXin-min¹, LI Li², TIANYue-jie³

1. General Hospital of Jinan Iron&Steel Group, Shandong Jinan 250101, China;
2. Shandong Institute of Pharmaceutical Industry, Shandong Jinan 250033, China;
3. Shandong Center for ADR Monitoring, Shandong Jinan 250013, China

Received:2011-01-13 Revised:2015-08-27 Online:2011-04-10 Published:2015-08-27

摘要/Abstract

摘要： 对近几年来各国学者对HLA-B*1502等位基因与抗癫痫药物致不同种族严重皮肤反应关系的研究进行了综述，并对可能的机制进行初步分析，以期对合理使用抗癫痫药物，预防和减少严重不良反应提供思路。

关键词: HLA-B*, 1502, 抗癫痫药, 种族, 严重皮肤不良反应

Abstract: To present a review on the research of the association between HLA-B*1502 allele and the severe cutaneous adverse reactions in different race induced by anti-epileptic drugs in recent years. The mechanisms were preliminary analysised to provide reference on the rational use of anti-epileptic drugs and prevent and reduce the serious adverse events.

Key words: HLA-B*, 1502, antiepileptic-drug, race, severe cutaneous adverse drug reactions

中图分类号:

R971.6

程新民,李莉, 田月洁. HLA-B*1502等位基因与抗癫痫药物致不同种族严重皮肤不良反应的研究进展[J]. 中国药物警戒, 2011, 8(4): 237-239.

CHENG Xin-min, LI Li, TIANYue-jie. Recent Advance on the Association Between HLA-B*1502 Allele and Severe Cutaneous Adverse Reactions in Different Race Induced by Anti-epileptic Drugs[J]. Chinese Journal of Pharmacovigilance, 2011, 8(4): 237-239.

参考文献

[1] Roujeau J C. Stern R S.Severe adverse cutaneous reactions to drugs[J]. N Engl J Med, 1994,331(19):1272-1285.
[2] Chung W H, Hung S I, Hong H S, et al. Medical genetics: a marker for Stevens-Johnson syndrome[J]. Nature, 2004,428(6982):486.
[3] Hung S I, Chung W H, Jee S H, et al. Genetic susceptibility to carbamazepine induced cutaneous adverse drug reactions[J].Phar-macogenet Genomics,2006,16（4）:297-306.
[4] Miller J W. Of race, ethnicity and rash: the genetics of antie- pileptic drug-induced skinreactions[J].Epilepsy Curr, 2008,8(5):120-121.
[5] Wu X T, Hu F Y, An D M, et al.Association between carba- mazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China[J]. Epilepsy Behav, 2010,19(3):405-408.
[6] An D M, Wu X T, Hu F Y, et al. Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B* 1502 in a Han Chinese population[J].Epilepsy Res,2010,92(2-3):226-230.
[7] Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated withHLA-B*1502 allele in Thai population[J].Epilepsia,2008,49(12):2087-2091.
[8] Tassaneeyakul W, Tiamkao S, Jantararoungtong T, et al. Association between HLA-B*1502 and carbamazepine-induced severe cutan- eous adversedrug reactions in a Thai population[J].Epilepsia, 2010,51(5):926-930.
[9] Mehta T Y, Prajapati L M, Mittal B,et al. Association of HLA- B*1502 allele and carbamazepine-induced Stevens-Johnsonsy- ndrome among Indians[J]. Indian J Dermatol Venereol Leprol.2009,75(6):579-582.
[10] Kaniwa N, Saito Y, Aihara M,et al.HLA-B locus in Japanese patients with anti-epileptics and allopurinol-relatedStevens- Johnson syndrome and toxic epidermal necrolysis[J].Pharmacogenomics,2008,9(11):1617-1622.
[11] Ikeda H, Takahashi Y, Yamazaki E,et al.HLA class I markers in Japanese patients with carbamazepine-induced cutaneousadverse reactions[J].Epilepsia,2010,51(2):297-300.
（因版面有限,部分参考文献省略,如有需要,请联系编辑部）